TIEP

This combination is known as TIEP (Tamoxifen, Ifosfamide, Epirubicin, and Cisplatin) chemotherapy and has been studied in clinical trials for various types of cancer, particularly non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The TIEP regimen typically consists of: - Tamoxifen: 60 mg oral twice daily on days 1-3 - Ifosfamide: 2.4 g/m² intravenous infusion over 60 minutes on day 2 (with mesna uroprotection) - Epirubicin: 40 mg/m² IV bolus on day 2 - Cisplatin: 50 mg/m² IV over 60 minutes on day 2 This combination has been administered every 4 weeks for up to six cycles in clinical trials. ## Clinical Evidence Phase II trials of TIEP have been conducted in both chemonaive inoperable non-small-cell lung cancer patients and in patients who had failed previous chemotherapy. In one study of previously treated NSCLC patients, the response rate was 20% with a median time to disease progression of 4.9 months and median survival of 7.7 months[2]. The major toxicity observed with this regimen is myelosuppression. Grade 3 or 4 neutropenia occurred in 60% of patients during treatment in one study, with febrile neutropenia occurring in some patients. Grade 3 thrombocytopenia was also observed. However, non-myelosuppressive toxicities were generally few and mild in severity[2]. Similar combination regimens without tamoxifen (IEP - Ifosfamide, Epirubicin, and Cisplatin) have been studied in other cancers such as osteosarcoma, where they showed activity with reasonable tolerability[6]. A variation of this combination using consecutive low-dose cisplatin with ifosfamide and epirubicin (CLD-IEP) has also been studied in uterine sarcoma[8][9]. The TIEP combination appears to be an active regimen with acceptable toxicity profiles in various cancer types, particularly in lung cancer patients who have failed previous chemotherapy.

Other names

Cisplatin + Epirubicin + Ifosfamide + TamoxifenTamoxifen, Ifosfamide, Epirubicin, and Cisplatin